DexCom (DXCM)

• Market cap: $35.6B
• 1 day: -0.63%
• 5 days: 3.20%
• 1 month: 2.85%
• 3 months: 19.23%
• 6 months: 21.28%
• Year to date: 13.10%
• 1 year: -23.72%
• 5 years: 21.93%
• 10 years: 459.07%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Employees: 9,600

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

59% more first-time investments, than exits

New positions opened: 178 | Existing positions closed: 112

43% more call options, than puts

Call options by funds: $716M | Put options by funds: $499M

15% more capital invested

Capital invested by funds: $24B [Q3] → $27.6B (+$3.59B) [Q4]

3% more funds holding

Funds holding: 870 [Q3] → 896 (+26) [Q4]

1.44% more ownership

Funds ownership: 89.41% [Q3] → 90.85% (+1.44%) [Q4]

1% less repeat investments, than reductions

Existing positions increased: 316 | Existing positions reduced: 318

22% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $82 8% downside
• Avg. target: $98 11% upside
• High target: $115 30% upside

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

Canaccord Genuity William Plovanic 67% 1-year accuracy 33 / 49 met price target	16% upside $103	Buy Maintained	14 Feb 2025
Morgan Stanley Patrick Wood 64% 1-year accuracy 7 / 11 met price target	8% downside $82	Equal-Weight Maintained	14 Feb 2025
Redburn Atlantic Issie Kirby 50% 1-year accuracy 2 / 4 met price target	30% upside $115	Buy Upgraded	3 Feb 2025
Baird Jeff Johnson 42% 1-year accuracy 11 / 26 met price target	17% upside $104	Outperform Upgraded	16 Jan 2025
Citigroup Joanne Wuensch 73% 1-year accuracy 35 / 48 met price target	3% upside $91	Buy Maintained	11 Dec 2024